FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses) 1. Name and Address of Reporting Person* BALEZENTIS CARL W			2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE			3. Date of Earliest Transaction (Month/Day/Year) 01/22/2009				X Officer (give title below) Other (specify below) Pres., Enzo Life Sciences,Inc.						
NEW YORK, NY 10003			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City)		(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)		ity	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any	(Instr. 8)	(A) o	4. Securities Acquire (A) or Disposed of ((Instr. 3, 4 and 5)		Beneficia	ally Owned Following I Transaction(s)		6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership
				(Month/Day/Year)	Code	V Amoi	(A) or (D)	Price	`	nd 4)			(Instr. 4)
Common S	Stock		01/22/2009		A	10,0	00 A	<u>(1)</u>	22,696	<u>(2)</u>		D	
		reparate fine re	r caen class of secur	nies beneficially ov		contained	ho respoi	m are	e not requ		ormation spond unlestrol number	s	1474 (9-02)
		reparate mie re	Table II - I	Derivative Securiti	es Acquire	Persons w contained the form d	tho responding this for isplays a	m are curre	e not requently valid	uired to res	spond unles	s	1474 (9-02)
(Instr. 3) Pr		3. Transaction Date (Month/Day/	Table II - I (n 3A. Deemed Execution Dat year)	Derivative Securities, puts, calls, was te, if Transaction Code (Instr. 8)	es Acquire	Persons w contained the form d	rho respondin this for isplays a lof, or Benertible securicisable ion Date	rm are curre eficial rities) 7. T Ame Und	e not requently valid	OMB conf	spond unles	f 10. Ownersh Form of Derivati Security Direct (I or Indire	11. Nature of Indire Benefici Owners! (Instr. 4)
Derivative Security (Instr. 3)	Conversion r Exercise rice of Derivative	3. Transaction	Table II - I (n 3A. Deemed Execution Dat year)	Derivative Securities, puts, calls, was te, if Transaction Code (Instr. 8)	es Acquires prants, opt 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,	Persons we contained the form ded, Disposed tions, converse of the Exercise of	tho respoi in this for isplays a of, or Ben rtible secu ercisable ion Date y/Year)	rm are curre reficial rities) 7. T Amel Und Secu (Ins. 4)	e not requently valid Ily Owned Title and ount of derlying urities	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(f 10. Ownersh Form of Derivati Security Direct (I or Indire	11. Nature of Indire Benefici Owners! (Instr. 4)

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
BALEZENTIS CARL W C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10003			Pres., Enzo Life Sciences,Inc.			

Signatures

/s/ Carl Balezentis	01/26/2009
***Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) Carl Balezentis was granted 10,000 shares of restricted Common Stock on January 22, 2009.
- (2) Includes 776 shares of Common Stock held in the Company's 401(k) plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.